Harvest One launches Satipharm reformulated CBD capsules in Europe

Harvest One Cannabis Inc (CVE:HVT) (OTCMKTS:HRVOF) announced late Tuesday that its wholly-owned medical subsidiary Satipharm Limited has launched European sales of its recently reformulated CBD capsules.

The first product to market is the Satipharm 10 milligram CBD Gelpell capsule, now available at www.satipharm.com that is designed to improve the body’s absorption of cannabidiol (CBD). Bricks-and-mortar distribution of the 10 milligrams CBD Gelpell capsules will follow with the help of major retailers in the United Kingdom, the European Union, and Canada, said the company.

CBD is the non-intoxicating marijuana extract being credited with helping to treat a host of medical problems from epileptic seizures to anxiety and sleeplessness.

BIG PICTURE: Harvest One shakes up the global cannabis space with a full house of brands

Satipharm’s Gelpell technology improves the body’s absorption of CBD and other cannabinoids through a patented formulation of CBD hemp extract contained in seamless Gelpell gelatine biospheres. The company said the “Gelpell biospheres are placed in gastro-resistant capsules” ensuring the timely release of CBD in the small intestine, thereby ensuring patients receive a consistent dose of CBD in every Satipharm CBD Gelpell capsule.

“We are delighted with the launch of Satipharm’s new website and eCommerce platform, making our clinically proven CBD Gelpell capsules available to consumers across Europe,” said Satipharm president Jonathan Hartshorn. “With our focus on consumer education, GMP certified products, and superior bioavailability, we feel strongly that consumers will adopt Satipharm’s CBD Gelpell capsules as the product of choice for CBD delivery in the marketplace.”

Vancouver-based Havest One services medical and recreational cannabis markets in Canada and internationally.

“The launch of Satipharm’s patented CBD Gelpell formulated capsules is an integral part of Harvest One’s health and wellness strategy,” said Harvest One CEO Grant Froese. “We are very pleased to bring this innovative delivery technology to market and we look forward to the launch of additional product lines as we advance our health and wellness strategy in regulated markets around the world.”

Clinical Trials

Satipharm’s proprietary CBD Gelpell capsules have been used in two separate clinical trials. The Phase 1 clinical trial conducted in 2016, demonstrated the safety and superior bioavailability of Satipharm’s CBD Gelpell capsules in comparison to an oromucosal formulation or spray.

Similarly, the Phase 2 clinical trial in 2018, further demonstrated that Satipharm’s CBD capsules significantly reduced monthly seizures in treatment-resistant children when added to current medications. The open-label, single-centre clinical study to evaluate the safety, tolerability and efficacy of Satipharm CBD capsules as an adjunctive treatment reduced epileptic seizures in paediatric patients with “very severe, uncontrolled, treatment-resistant” epilepsy (TRE) by a remarkable 73.4% in the 12-week treatment period, showed the study. 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Story by ProactiveInvestors